grant
Cellular engineering to improve the efficacy and specificity of targeted immunotherapy
Organization MASSACHUSETTS INSTITUTE OF TECHNOLOGYLocation CAMBRIDGE, UNITED STATESPosted 1 Sept 2021Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY2026AddressAdoptive Cell TransfersAdverse ExperienceAdverse eventAffectAffinityAmino AcidsAnimal ModelAnimal Models and Related StudiesAntigen TargetingAntigenic DeterminantsAntigensAutoantigensAutologous AntigensAwardB cell malignancyB lymphoid malignancyBindingBinding DeterminantsBiochemistryBiological ChemistryBody TissuesBypassCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCMVCancer ModelCancer TreatmentCancer cell lineCancerModelCancersCell Communication and SignalingCell SignalingCell Surface AntigensCell TherapyCessation of lifeClinical TrialsCollectionComplexCoupledCytomegalovirusDNA Molecular BiologyDNA TherapyDeathDevelopmentDirected Molecular EvolutionEngineeringEnsureEpitopesFDA approvedFaceGene Transfer ClinicalGenerationsGeneticGenetic InterventionGoalsHCMVHL-A AntigensHLA AntigensHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHematopoietic Cell TumorHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHigh Throughput AssayHuman GenomeHuman Leukocyte AntigensImmune mediated therapyImmune signalingImmune systemImmunological Surface MarkersImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyIn VitroIndividualInfiltrationIntracellular Communication and SignalingLearningLeukocyte AntigensLibrariesLigandsLogicMHC ReceptorMajor Histocompatibility Complex ReceptorMalignant Hematologic NeoplasmMalignant Hematopoietic NeoplasmMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMethodsModificationMolecular BiologyMolecular InteractionPeptidesPhage DisplayPhasePopulationPostdocPostdoctoral FellowProliferatingProtein EngineeringProteinsR-Series Research ProjectsR01 MechanismR01 ProgramReceptor ProteinResearchResearch AssociateResearch GrantsResearch Project GrantsResearch ProjectsResearch ProposalsResidualResidual stateSalivary Gland VirusesScanningSelf-AntigensSignal TransductionSignal Transduction SystemsSignalingSolid NeoplasmSolid TumorSpecificityStatistical Data AnalysesStatistical Data AnalysisStatistical Data InterpretationSurface AntigensT Cell SpecificityT cell infiltrationT cell receptor based immunotherapyT cell receptor cellular immunotherapyT cell receptor engineered therapyT cell receptor immunotherapyT cells for CART-Cell ActivationT-Cell Antigen Receptor SpecificityT-Cell Antigen ReceptorsT-Cell Immunologic SpecificityT-Cell ProliferationT-Cell ReceptorT-Cell Receptor GenesT-Cell Receptor SpecificityT-Cell Receptor TherapyT-Cell Receptor TreatmentT-Cell Receptor based TherapyT-Cell Receptor based TreatmentT-CellsT-LymphocyteT8 CellsT8 LymphocytesTCR T cell immunotherapyTCR T cell therapyTCR TherapyTCR based T cell immunotherapyTCR based TherapyTCR based immune therapyTCR based immunotherapyTCR based treatmentTCR immunotherapyTcR GenesTestingTherapeuticTissuesToxic effectToxicitiesTrainingTumor AntigensTumor CellTumor-Associated AntigenViralWorkYeastsactivate T cellsadoptive cell therapyadoptive cellular therapyaminoacidanti-cancer immunotherapyanti-cancer therapyanticancer immunotherapyautoreactive T cellbiological signal transductionblood cancercancer antigenscancer immunotherapycancer microenvironmentcancer of bloodcancer of the bloodcancer therapycancer-directed therapycancer/testis antigencell based interventioncell engineeringcell killingcell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular engineeringcellular therapeuticcellular therapychimeric antigen T cell receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical efficacycombatcross reactivitycytomegalovirus groupdesigndesigningdevelopmentaldirected evolutionengineered T cellsexhaustionexperiencefacesfacialgene repair therapygene therapygene-based therapygenetic protein engineeringgenetic therapygenetically engineered T-cellsgenomic therapyhigh throughput screeninghuman whole genomeimmune microenvironmentimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive responseimmunosuppressive tumor microenvironmentimmunotherapy for cancerimmunotherapy of cancerimprovedin vivoin vivo Modelinsightinterestmalignancymodel of animalmouse modelmurine modelneoplasm/cancerneoplastic cellnew approachesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel approachesnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel strategiesnovel strategynovel therapeuticsnovel therapypost-docpost-doctoralpost-doctoral traineeprogramsprotein designreceptorresearch associatesresponsescreeningscreeningsself-reactive T cellstatistical analysissuccesssynthetic biologysystemic toxicitythymus derived lymphocytetooltransgenic T- cellstumortumor immune microenvironmenttumor microenvironmenttumor specificitytumor-immune system interactionstumor-specific antigenviral microbiomevirome
Description preview
Project Summary/Abstract
Adoptive cell therapy (ACT) is a promising therapeutic approach for the treatment of cancer. However,
the initial success of ACT has been limited to chimeric antigen receptor (CAR)-T cell therapies for hematological
malignancies. Applying this cell therapy to solid tumors is challenged by the lack of targetable tumor…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click